Deadline on March 17, 2014 in Lawsuit for Investors in Aegerion Pharmaceuticals, Inc. (AEGR) Shares Announced by Shareholders Foundation

SF logo

SAN DIEGO, Feb. 5, 2014 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a deadline to get actively involved is coming up on March 17, 2014 in the lawsuit filed on behalf of certain investors in shares Aegerion Pharmaceuticals, Inc. (AEGR) over alleged Securities Laws Violations by Aegerion Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements made between March 15, 2012 and January 9, 2014.

If you purchased a significant amount of shares of Aegerion Pharmaceuticals, Inc. (AEGR) between March 15, 2012 and January 9, 2014, and / or if you purchased AEGR shares prior to March 2012 and currently hold any of those shares, you have certain options and you should contact the Shareholders Foundation before March 17, 2014 at or call +1(858) 779 - 1554.

The plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or failed to disclose to Aegerion Pharmaceuticals' investors that Aegerion Pharmaceuticals, Inc. marketed its drugs in violation of the FDCA, that as a result, Aegerion Pharmaceuticals, Inc. faced heightened regulatory scrutiny by the FDA and other governmental bodies, and that as a result of the foregoing, Aegerion Pharmaceuticals Inc's statements were allegedly materially false and misleading at all relevant times.

On November 8, 2013, news reports revealed that Aegerion Pharmaceuticals, Inc. received an FDA Warning Letter in connection with statements the Company's CEO made regarding JUXTAPID capsules, during broadcast interviews on CNBC's television show, "Fast Money," that aired on June 5, 2013, and October 31, 2013.

Then on January 9, 2014, Aegerion Pharmaceuticals, Inc. disclosed that it has received a subpoena from the United States Department of Justice, represented by the U.S. Attorney's Office in Boston, MA, requesting documents regarding the Company's marketing and sale of JUXTAPID in the United States.

AEGR shares declined from $97.24 per share in October 2013 to $56.74 per share in late January 2014.

The plaintiff seeks to recover damages on behalf of all purchasers of Aegerion Pharmaceuticals, Inc. (AEGR) common stock between March 15, 2012 and January 9, 2014.

Those who purchased shares of Aegerion Pharmaceuticals, Inc. have certain options and should contact the Shareholders Foundation, Inc. by e-mail at or call +1 (858) 779-1554.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT: Shareholders Foundation, Inc. Trevor Allen +1 (858) 779-1554 3111 Camino Del Rio North Suite 423 San Diego, CA 92108

Source:Shareholders Foundation, Inc.